JP Morgan maintains its Overweight rating and $60 target price on Baxter International BAX as Alzheimer's takes center stage in the company's pipeline.
JP Morgan notes, "On Tuesday at the J.P. Morgan Healthcare Conference, Baxter provided a detailed update on a number of products within its pipeline. We've talked a lot about the
puts and takes the company will face heading into 2012 and still believe the Street is a little too high on the bottom line for 2012 (JPMe $4.56 vs Street consensus at $4.64). Yet, with the 2012 issues increasingly understood, the attention at the conference was on a number of updates the company provided on its pipeline. We continue to see Baxter as an attractive second half story given the HyQ launch as well as a number of assets that should gain increased focus during the year."
BAX closed at $50.18 per share on Tuesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in